Spica Healthcare — Unit of Grover Hospital, Bathinda
HomeHealth Guides & BlogsPrecision Oncology & Cancer GenomicsHomologous Recombination Deficiency (HRD) & PARP Inhibitor Maintenance in Ovarian & Pancreatic Malignancies: Olaparib & Niraparib Protocols
Precision Oncology & Cancer Genomics

Homologous Recombination Deficiency (HRD) & PARP Inhibitor Maintenance in Ovarian & Pancreatic Malignancies: Olaparib & Niraparib Protocols

10 min read
Sep 12, 2026
Spica Healthcare Clinical & Surgical Protocol Illustration #142

Clinical Summary & Key Takeaways

An in-depth review on Homologous Recombination Deficiency (HRD) and PARP inhibitor maintenance (Olaparib, Niraparib) in ovarian and pancreatic cancers, synthetic lethality mechanisms, and hematologic toxicity management.

CRITICAL CLINICAL RED FLAG: Persistent macroscopic cytopenias (Hb <8 g/dL, Platelets <50,000/mcL, ANC <1000/mcL) lasting >4-6 weeks despite PARP inhibitor dose reductions warrant bone marrow aspiration and cytogenetic workup to rule out Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML).

1. The Concept of Synthetic Lethality in HRD-Positive Tumors

Normal cells utilize two distinct DNA repair mechanisms: Poly(ADP-ribose) Polymerase (PARP) enzymes repair single-strand DNA breaks via Base Excision Repair (BER), whereas BRCA1/BRCA2 and the Homologous Recombination (HR) pathway repair catastrophic double-strand breaks. In tumor cells harboring germline/somatic BRCA mutations or Homologous Recombination Deficiency (HRD), pharmacological PARP inhibition (Olaparib, Niraparib, Rucaparib) traps PARP at DNA replication forks, converting single-strand lesions into unrepairable double-strand breaks that trigger selective cancer cell apoptosis—a biological mechanism termed "Synthetic Lethality."

  • Advanced High-Grade Serous Ovarian Cancer (SOLO-1 Trial): First-line maintenance Olaparib in BRCA-mutated advanced ovarian cancer demonstrates a median progression-free survival of 56.0 months versus 13.8 months for placebo, achieving unprecedented 5-year remission rates.

  • Metastatic Pancreatic Adenocarcinoma (POLO Trial): Maintenance Olaparib in germline BRCA-mutated pancreatic cancer whose disease had not progressed during frontline platinum-based chemotherapy nearly doubled progression-free survival (7.4 vs. 3.8 months).

2. Clinical Biomarkers: Beyond BRCA1/2 Testing

Genomic Scar Testing / Genomic Instability Score (GIS) evaluates Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-Scale State Transitions (LST). Patients with HRD-positive tumors (GIS score >=42 or Myriad myChoice HRD positive) without BRCA mutations derive substantial clinical benefit from PARP inhibitor maintenance combined with Bevacizumab (PAOLA-1 regimen).

"Synthetic lethality with PARP inhibitors has transformed advanced ovarian and pancreatic cancer maintenance, converting platinum sensitivity into durable, years-long remission." — Dr. Neha Gupta

3. Hematologic Toxicity Monitoring Protocol

Baseline complete blood counts (CBC) must be monitored weekly for the first month, bi-weekly for the next 2 months, and monthly thereafter. For Grade 3/4 anemia or thrombocytopenia, interrupt treatment until recovery to <=Grade 1, then resume with structured dose decrements (e.g., Olaparib 300 mg BID reduced to 250 mg BID; Niraparib individualized baseline dosing based on weight <77 kg or platelets <150,000/mcL).

4. Peer-Reviewed References & Clinical Guidelines

1. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (SOLO-1). New England Journal of Medicine (NEJM), 2018; 379: 2495-2505.

2. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer (POLO Trial). NEJM, 2019; 381: 317-327.

3. Ray-Coquard I, Pautier P, Colonval S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer (PAOLA-1/ENGOT-ov25). NEJM, 2019; 381: 2416-2428.

Frequently Asked Patient Questions

Yes. Over 85% of modern systemic cancer protocols are delivered safely in dedicated outpatient daycare infusion suites with continuous electronic vitals monitoring, allowing patients to sleep in their own beds at home the same night.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Senior Consultant & Clinical Director — Medical Oncology

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Share this medical guide:
WhatsApp
Director-Led Clinical Breakthroughs

Signature Surgical Innovations & Techniques

Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

1 of 13
Comprehensive Bone Cancer Oncology & Limb Preservation
Click to Watch Video Demonstration
95%+ Limb Salvage & MAP Chemotherapy
Multidisciplinary Limb Salvage, MAP Chemotherapy & Modular Megaprosthetics

Comprehensive Bone Cancer Oncology & Limb Preservation

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.

Key Advantages Over Conventional Surgery:
Coordinated Surgical & Medical Oncology: Seamless dual leadership under Dr. Deepak Garg & Dr. Neha Gupta
95%+ Limb Preservation Rate: Wide oncological bone resection avoiding traumatic limb amputations
High-Grade Sarcoma Chemotherapy: Standardized MAP and VIDE protocols delivering high tumor necrosis rates (>90%)
Custom Modular Megaprostheses: Immediate joint restoration with biological tendon ingrowth collars
Why Families & Physicians Trust Spica

World-Class Clinical Precision, Built on Compassion

Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.

AIIMS & Tata Memorial Alumni25+ Yrs Combined Senior Leadership

15,000+ Complex Surgeries & 100% Director-Led Evaluations

Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.

15,000+Surgeries Completed
95%+Limb Salvage Rate
<0.3%Infection Benchmark
Pre-Op 3D Virtual Planning 100% Direct Director OPD Day-1 Walking Protocol
Sub-Millimeter Accuracy

3D Navigated Robotics & Day-1 Walking

Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.

ROSA Robotics & Stryker Nav
Malwa Punjab Exclusive

Limb-Salvage Over Amputation

South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.

Modular Megaprosthesis
0-Out-Of-Pocket Options

100% Cashless PM-JAY & TPAs

Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.

Ayushman + 30+ TPAs Empanelled
24/7 Tertiary Ready

Class-100 Laminar Flow OTs & ICU

Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.

Spica Healthcare Bathinda
Expert Surgical Directors

Meet the Doctors at Spica Healthcare

Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Dr. Neha Gupta

Senior Consultant & Clinical Director — Medical Oncology

13+ Yrs Exp

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Medical Oncology & ChemotherapyImmunotherapy & Targeted OncologyPrecision Oncology & Cancer GenomicsPreventive Cancer ScreeningPalliative & Supportive OncologyHormonal TherapyComprehensive Cancer Treatments
Dr. Deepak Garg - Director & Senior Joint Replacement, Spine and Orthopaedic Oncologist

Dr. Deepak Garg

Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery

16+ Yrs Exp

MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)

Orthopaedic Oncology & Bone Tumors3D Robotic Joint ReplacementSports Injuries & ArthroscopyTrauma & Fracture ReconstructionGeneral Orthopaedics & Spine CareComprehensive Cancer Treatments
Community Health & Academic Outreach

Upcoming Health Camps & Academic Events

Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.

Curious what families & patients experience

Hear what our patients are saying

Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.

Health Knowledge & Clinical Guides

Doctor-Authored Health Guides

Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.